CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:An Unusual Pattern of Hepatic Involvement in Plasma Cell Leukemia.
An Unusual Pattern of Hepatic Involvement in Plasma Cell Leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
浆细胞白血病(PCL)是一种罕见的侵袭性浆细胞肿瘤,预后极差。PCL的器官受累,包括脾脏和肝脏,较为罕见,通常表现为肿瘤性浆细胞的弥漫性浸润。我们报告一例PCL患者,在联合化疗后,于骨髓移植前检查中通过正电子发射断层扫描发现肝脏病变。肝肿块活检显示肝实质内片状非典型浆细胞浸润。免疫组化染色显示CD138和MUM1强表达。原位杂交显示lambda轻链限制性,证实为患者已知PCL的肝脏受累。随后建议该患者接受二线CAR-T 治疗,以替代原计划的自体移植。本病例展示了PCL的一种不寻常表现,以及对于侵袭性浆细胞肿瘤患者,对肝脏病变保持广泛鉴别诊断的重要性,因其对准确诊断和治疗方案的制定具有重要意义。
Plasma cell leukemia (PCL) is a rare and aggressive plasma cell neoplasm associated with dismal outcomes. Organ involvement in PCL, including the spleen and the liver, is rare and commonly manifests as diffuse infiltration of neoplastic plasma cells.
We report a patient with PCL, status post combination chemotherapy, identified to have hepatic lesions on positron emission tomography as part of a pre-bone marrow transplant workup. Biopsy of the hepatic mass revealed sheets of atypical plasma cells within the hepatic parenchyma. Immunohistochemical staining showed strong expression of CD138 and MUM1. In situ hybridization demonstrated lambda light chain restriction, confirming hepatic involvement of the patient's known PCL.
The patient was subsequently recommended for second-line CAR-T therapy in lieu of the planned autologous transplant. This case demonstrates an unusual manifestation of PCL and the importance of maintaining a broad differential diagnosis for hepatic lesions in patients with aggressive plasma cell neoplasms due to its implications for accurate diagnosis and treatment planning.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。